American Vanguard Corp (AVD) company profile
Close on Nov 13, 2026Market cap $25.00MP/E –Yield –
About American Vanguard
Agricultural Chemicals, SIC 2870
American Vanguard Corporation develops, manufactures, and markets chemical, biological, and biorational solutions for agricultural, commercial, and consumer applications. The company operates through a single reportable segment, synthesizing active ingredients and formulating products such as insecticides, fungicides, herbicides, soil health treatments, plant nutrition aids, molluscicides, growth regulators, and soil fumigants. It also offers specialized closed delivery systems for product application. The business serves growers, retailers, and end-users, primarily selling to national distribution firms, agricultural buying groups, and cooperatives.
The company operates six manufacturing facilities, consisting of four chemical synthesis and formulation sites alongside two biological fermentation plants located in the United States and Mexico. Beyond domestic operations, it maintains sales offices, wholly owned distributors, or commercial agents across Central and South America, Australia, New Zealand, and India. American Vanguard Corporation is incorporated in Delaware and maintains its principal executive headquarters in Newport Beach, California.
Summary of the business section of American Vanguard's latest annual report, written by StockData.
Company profile
Company
- Legal name
- American Vanguard Corp
- Founded
- 1969
- Headquarters
- Newport Beach, CA
- Address
- 4695 Macarthur Court 92660
- Phone
- (949) 260-1200
- Website
- american-vanguard.com
- Employees
- 739, Dec 31, 2025
- Industry
- Agricultural Chemicals
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Costa Mesa, California
Stock & identifiers
- Ticker
- AVD
- Exchange
- NYSE
- IPO date
- Mar 3, 1987
- Shares outstanding
- 29M, Feb 20, 2026
- Public float
- $111.10M, Jun 30, 2025
- Filer category
- Accelerated filer
- Stock splits
- 4-for-3, Apr 18, 2006; 2-for-1, Apr 18, 2005; 3-for-2, Apr 19, 2004; 3-for-2, Apr 14, 2003; 4-for-3, Apr 15, 2002; 11-for-10, Mar 28, 2001; 11-for-10, Mar 29, 2000; 5-for-4, Nov 2, 1988
- SEC CIK
- 5981
- CUSIP
- 030371108
- ISIN
- US0303711081
- FIGI
- BBG000DPXVW9
- Share class FIGI
- BBG001S8KSH7
- LEI
- 529900GWI78WZA5M9783
- EIN
- 95-2588080
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Douglas Kaye | CHIEF EXECUTIVE OFFICER | 306,778 |
| David` T. Johnson | See Remarks | 71,671 |
| Jared Straley | SVP Operations & Supply Chain | 10,000 |
| Timothy J. Donnelly | See Remarks | 85,102 |
| Michael Joseph DiPaola | Chief Commercial Officer | 10,000 |
| Nolteanous Gilliam | SVP Manufacturing | 4,245 |
| Shirin Khosravi | CHRO | 4,377 |
| Peter Eilers | See Remarks | 32,177 |
| Keith M. Rosenbloom | Director | 638,064 |
| Steven D. Macicek | Director | 99,711 |
| Rubin J. McDougal | Director | 31,872 |
| Mark R. Bassett | Director | 89,919 |
| Patrick E. Gottschalk | Director | 223,577 |
| Marisol Angelini | Director | 68,762 |
| de Mino Carmen Tiu | Director | 24,407 |
| Emer Gunter | Director | 33,723 |
| Scott Baskin | Director | 41,997 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.07M | $770.73K | $585.24K | $25 | $119 |
| FY2024 | $1.68M | $339.58K | $680.44K | $24 | $113 |
| FY2023 | $2.51M | -$471.65K | $567.67K | $72 | $105 |
| FY2022 | $2.85M | $3.43M | $729.91K | $141 | $115 |
| FY2021 | $2.46M | $3.09M | $708.60K | $106 | $125 |
| FY2020 | $2.18M | $1.93M | $645.12K | $100 | $100 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Douglas A. Kaye III Chief Executive Officer | $650.00K | $235.95K | $183.53K | $1.07M | -36% |
| David T. Johnson Chief Financial Officer | $445.94K | $97.14K | $169.09K | $712.17K | -26% |
| Timothy J. Donnelly Chief Legal Officer, General Counsel & Secretary | $400.00K | $87.12K | $145.08K | $632.20K | -26% |
| Shirin Khosravi Chief Human Resources Officer | $300.00K | $67.68K | $133.56K | $501.24K | -12% |
| Shayne Wetherall Chief Executive Officer of Specialty Business | $332.75K | $85.33K | $77.28K | $495.36K | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“The Company employed 739 employees as of December 31, 2025.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?